Janux Therapeutics (JANX) Competitors $59.61 -1.95 (-3.17%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends JANX vs. RDY, SRPT, CTLT, PCVX, QGEN, ITCI, ROIV, ASND, RVMD, and LNTHShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Janux Therapeutics (NASDAQ:JANX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership. Do analysts prefer JANX or RDY? Janux Therapeutics currently has a consensus target price of $89.90, indicating a potential upside of 50.81%. Dr. Reddy's Laboratories has a consensus target price of $17.00, indicating a potential upside of 17.44%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer JANX or RDY? In the previous week, Janux Therapeutics had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.44 beat Janux Therapeutics' score of 0.64 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in JANX or RDY? 75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 29.4% of Janux Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor JANX or RDY? Dr. Reddy's Laboratories received 281 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.18% of users gave Janux Therapeutics an outperform vote while only 59.44% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4070.18% Underperform Votes1729.82% Dr. Reddy's LaboratoriesOutperform Votes32159.44% Underperform Votes21940.56% Which has more volatility and risk, JANX or RDY? Janux Therapeutics has a beta of 3.29, meaning that its share price is 229% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Which has better earnings and valuation, JANX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$13.05M239.75-$58.29M-$1.17-50.95Dr. Reddy's Laboratories$299.87B0.04$668M$0.6322.98 Is JANX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.81% compared to Janux Therapeutics' net margin of -463.91%. Dr. Reddy's Laboratories' return on equity of 18.53% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Dr. Reddy's Laboratories 17.81%18.53%13.01% SummaryJanux Therapeutics beats Dr. Reddy's Laboratories on 10 of the 19 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.13B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-50.9510.75135.1817.53Price / Sales239.75287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book7.995.394.884.92Net Income-$58.29M$152.04M$118.97M$225.78M7 Day Performance-6.05%-4.32%16.19%-1.58%1 Month Performance23.88%2.80%16.02%6.67%1 Year Performance477.06%17.30%34.95%22.48% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics3.6007 of 5 stars$59.61-3.2%$89.90+50.8%+474.8%$3.13B$13.05M-50.9530RDYDr. Reddy's Laboratories2.1274 of 5 stars$14.75+2.0%$17.00+15.3%+8.6%$12.31B$299.87B22.9527,048SRPTSarepta Therapeutics4.9058 of 5 stars$127.00+2.7%$178.71+40.7%+35.2%$12.13B$1.64B98.971,314Insider TradePositive NewsCTLTCatalent2.7567 of 5 stars$63.48+0.7%$63.40-0.1%+53.0%$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.8076 of 5 stars$90.59+3.3%$147.50+62.8%+48.4%$11.29BN/A-19.07160QGENQiagen4.2311 of 5 stars$45.43+0.1%$51.15+12.6%+3.6%$10.37B$1.97B117.035,967ITCIIntra-Cellular Therapies4.1678 of 5 stars$84.54+1.8%$97.23+15.0%+32.9%$8.96B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.13+2.4%$17.93+47.8%+8.9%$8.83B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$136.02+4.7%$191.77+41.0%+16.0%$8.25B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.89-0.3%$63.67+41.8%+69.6%$7.55B$11.58M-12.54443Positive NewsLNTHLantheus4.3734 of 5 stars$94.50+1.6%$130.00+37.6%+21.9%$6.57B$1.50B15.42834Positive News Related Companies and Tools Related Companies RDY Competitors SRPT Competitors CTLT Competitors PCVX Competitors QGEN Competitors ITCI Competitors ROIV Competitors ASND Competitors RVMD Competitors LNTH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JANX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
